Benzinga Zenas BioPharma Touts Phase 3 Win, But Stock Crashes
Zenas BioPharma shares fall after Phase 3 obexelimab data in IgG4-RD showed a 56% flare risk reduction, as investors weigh competition from Amgen's FDA-approved Uplizna. read more
Zenas BioPharma shares fall after Phase 3 obexelimab data in IgG4-RD showed a 56% flare risk reduction, as investors weigh competition from Amgen's FDA-approved Uplizna. read more